drugset / Trial / NCT00358683
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizumab pegol until the drug is available for the Crohn's disease indication in Greece.
Timeline
- Start
- 2007-11
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | — | — |